- Home
- JFU vs BRTX Comparison
JFU vs BRTX Comparison
Compare JFU & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- BRTX
- Stock Information
- Founded
- JFU 2006
- BRTX 1997
- Country
- JFU China
- BRTX United States
- Employees
- JFU N/A
- BRTX 11
- Industry
- JFU Finance: Consumer Services
- BRTX Managed Health Care
- Sector
- JFU Finance
- BRTX Health Care
- Exchange
- JFU Nasdaq
- BRTX Nasdaq
- Market Cap
- JFU 17.8M
- BRTX 11.2M
- IPO Year
- JFU 2019
- BRTX N/A
- Fundamental
- Price
- JFU $1.37
- BRTX $1.62
- Analyst Decision
- JFU
- BRTX Strong Buy
- Analyst Count
- JFU 0
- BRTX 1
- Target Price
- JFU N/A
- BRTX $18.00
- AVG Volume (30 Days)
- JFU 6.8K
- BRTX 1.1M
- Earning Date
- JFU 01-01-0001
- BRTX 05-13-2025
- Dividend Yield
- JFU N/A
- BRTX N/A
- EPS Growth
- JFU N/A
- BRTX N/A
- EPS
- JFU 0.09
- BRTX N/A
- Revenue
- JFU $40,614,155.00
- BRTX $377,000.00
- Revenue This Year
- JFU N/A
- BRTX $482.76
- Revenue Next Year
- JFU N/A
- BRTX $212.24
- P/E Ratio
- JFU $15.56
- BRTX N/A
- Revenue Growth
- JFU N/A
- BRTX 189.55
- 52 Week Low
- JFU $1.13
- BRTX $1.03
- 52 Week High
- JFU $3.75
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- JFU 39.00
- BRTX 42.78
- Support Level
- JFU $1.38
- BRTX $1.46
- Resistance Level
- JFU $1.56
- BRTX $1.68
- Average True Range (ATR)
- JFU 0.08
- BRTX 0.22
- MACD
- JFU -0.02
- BRTX -0.01
- Stochastic Oscillator
- JFU 0.00
- BRTX 29.04
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.